MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
OTIC - Otonomy Inc
$2.88
-0.04(-1.20%)12:10:19 AM 3/2/2021
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Stock news

    02/26/2021OTIC
    Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?

    Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.

    02/25/2021OTIC
    Otonomy to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in three upcoming virtual conferences: A fireside chat at the Cowen 41st Annual Health Care Conference on March 4, 2021 at 12:50 p.m. ET / 9:50 a.m. PT;A pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference available on-demand starting at 7 a.m. E...

    02/22/2021OTIC
    ROCE Insights For Otonomy

    During Q4, Otonomy (NASDAQ:OTIC) brought in sales totaling $53.00 thousand. However, earnings decreased 2.2%, resulting in a loss of $10.29 million. Otonomy collected $50.00 thousand in revenue during Q3, but reported earnings showed a $10.52 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally repr...

    02/22/2021OTIC
    Otonomy stock loses half its value after disappointing trial results of vertigo treatment

    Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary endpoint. "We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis," said Chief Executive David Weber. He said the company's focus turns to the "strong pipeline," highli...

    02/22/2021OTIC
    Otonomy's OTIVIDEX Fails To Separate From Placebo In Inner Ear Disorder Study

    Otonomy Inc (NASDAQ: OTIC) has reported topline data from Phase 3 trial evaluating OTIVIDEX in patients with Ménière’s disease. It is an inner ear disorder that causes episodes of vertigo (spinning) and hearing loss. The study did not achieve the primary endpoint, which was the count of definitive vertigo days in month three for OTIVIDEX vs. placebo for the intent-to-treat population (n=148). However, the analysis achieved statistical significance for the per-protocol population (n=136). “Our fo...

    02/22/2021OTIC
    Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

    SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for OTIVIDEX vs. placebo for the intent-to-treat (ITT) population (n = 148; p value = 0.312) using the Negative Binomial Model....

    02/17/2021OTIC
    Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

    Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 44th Annual Mid...

    02/12/2021OTIC
    Otonomy (OTIC) Q4 2020 Earnings Call Transcript

    Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.